中国进展期乳腺癌共识指南2020(CABC3)

2020-10-30 《癌症进展》.2020.18(19):1945-9164.

在2015年发表的《中国进展期乳腺癌共识指南(CABC 2015)》(CABC2)的基础上,本指南进一步更新了进展期乳腺癌诊疗过程的一般原则、相关定义、疗效评估、治疗原则、用药策略及不良反应管理等内容

中文标题:

中国进展期乳腺癌共识指南2020(CABC3)

发布机构:

发布日期:

2020-10-30

简要介绍:

在2015年发表的《中国进展期乳腺癌共识指南(CABC 2015)》(CABC2)的基础上,本指南进一步更新了进展期乳腺癌诊疗过程的一般原则、相关定义、疗效评估、治疗原则、用药策略及不良反应管理等内容;专家组系统阅读国内外多项关于进展期乳腺癌的临床研究(包括回顾性的资料分析),整理并总结了现有最新的乳腺癌相关指南,召开会议组织专家进行了多次讨论,将在循证医学基础上达成的专家共识整理成文,为从事乳腺癌专业的医生,尤其是在治疗进展期乳腺癌方面,提供参考。同时也希望为患者了解乳腺癌提供帮助。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=中国进展期乳腺癌共识指南2020_CABC3_.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b4f171c002010a6e, title=中国进展期乳腺癌共识指南2020(CABC3), enTitle=, guiderFrom=《癌症进展》.2020.18(19):1945-9164., authorId=0, author=, summary=在2015年发表的《中国进展期乳腺癌共识指南(CABC 2015)》(CABC2)的基础上,本指南进一步更新了进展期乳腺癌诊疗过程的一般原则、相关定义、疗效评估、治疗原则、用药策略及不良反应管理等内容, cover=https://img.medsci.cn/20201119/1605715492042_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Fri Oct 30 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>在2015年发表的《中国进展期乳腺癌共识指南(CABC 2015)》(CABC2)的基础上,本指南进一步更新了进展期乳腺癌诊疗过程的一般原则、相关定义、疗效评估、治疗原则、用药策略及不良反应管理等内容;专家组系统阅读国内外多项关于进展期乳腺癌的临床研究(包括回顾性的资料分析),整理并总结了现有最新的乳腺癌相关指南,召开会议组织专家进行了多次讨论,将在循证医学基础上达成的专家共识整理成文,为从事乳腺癌专业的医生,尤其是在治疗进展期乳腺癌方面,提供参考。同时也希望为患者了解乳腺癌提供帮助。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=108145, tagName=进展期乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=285, guiderKeyword=乳腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11700, appHits=729, showAppHits=0, pcHits=1594, showPcHits=10971, likes=4, shares=44, comments=41, approvalStatus=1, publishedTime=Thu Nov 19 00:15:05 CST 2020, publishedTimeString=2020-10-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Nov 19 00:04:58 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 04:41:05 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国进展期乳腺癌共识指南2020_CABC3_.pdf)])
中国进展期乳腺癌共识指南2020_CABC3_.pdf
下载请点击:
评论区 (31)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1062411, encodeId=61f91062411dc, content=很好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Wed Oct 20 23:18:52 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060125, encodeId=ae841060125fd, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:14:45 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012718, encodeId=8a3a1012e18bf, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUaOs097vUd3tAkBeYXo0UuMtO6vOHicpCNV0xHiaMbaxn5hqtZbIdlZ4NHjXRFMpE5u0bGLAvRUjw/132, createdBy=916a2555838, createdName=刘荣泉, createdTime=Mon Aug 30 06:08:51 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001947, encodeId=f32d100194e57, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/15/b440bceb993c400094dff18d6231a29b.jpg, createdBy=acee2402916, createdName=1235ad0bm04暂无昵称, createdTime=Fri Jul 23 10:31:45 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997045, encodeId=afab99e04530, content=想要学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=Kwok21w, createdTime=Wed Jul 07 10:38:25 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-10-20 ms4000000670558531

    很好的资料

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1062411, encodeId=61f91062411dc, content=很好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Wed Oct 20 23:18:52 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060125, encodeId=ae841060125fd, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:14:45 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012718, encodeId=8a3a1012e18bf, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUaOs097vUd3tAkBeYXo0UuMtO6vOHicpCNV0xHiaMbaxn5hqtZbIdlZ4NHjXRFMpE5u0bGLAvRUjw/132, createdBy=916a2555838, createdName=刘荣泉, createdTime=Mon Aug 30 06:08:51 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001947, encodeId=f32d100194e57, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/15/b440bceb993c400094dff18d6231a29b.jpg, createdBy=acee2402916, createdName=1235ad0bm04暂无昵称, createdTime=Fri Jul 23 10:31:45 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997045, encodeId=afab99e04530, content=想要学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=Kwok21w, createdTime=Wed Jul 07 10:38:25 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-10-13 旭日东升a

    一起学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1062411, encodeId=61f91062411dc, content=很好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Wed Oct 20 23:18:52 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060125, encodeId=ae841060125fd, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:14:45 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012718, encodeId=8a3a1012e18bf, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUaOs097vUd3tAkBeYXo0UuMtO6vOHicpCNV0xHiaMbaxn5hqtZbIdlZ4NHjXRFMpE5u0bGLAvRUjw/132, createdBy=916a2555838, createdName=刘荣泉, createdTime=Mon Aug 30 06:08:51 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001947, encodeId=f32d100194e57, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/15/b440bceb993c400094dff18d6231a29b.jpg, createdBy=acee2402916, createdName=1235ad0bm04暂无昵称, createdTime=Fri Jul 23 10:31:45 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997045, encodeId=afab99e04530, content=想要学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=Kwok21w, createdTime=Wed Jul 07 10:38:25 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-08-30 刘荣泉

    学习一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1062411, encodeId=61f91062411dc, content=很好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Wed Oct 20 23:18:52 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060125, encodeId=ae841060125fd, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:14:45 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012718, encodeId=8a3a1012e18bf, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUaOs097vUd3tAkBeYXo0UuMtO6vOHicpCNV0xHiaMbaxn5hqtZbIdlZ4NHjXRFMpE5u0bGLAvRUjw/132, createdBy=916a2555838, createdName=刘荣泉, createdTime=Mon Aug 30 06:08:51 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001947, encodeId=f32d100194e57, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/15/b440bceb993c400094dff18d6231a29b.jpg, createdBy=acee2402916, createdName=1235ad0bm04暂无昵称, createdTime=Fri Jul 23 10:31:45 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997045, encodeId=afab99e04530, content=想要学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=Kwok21w, createdTime=Wed Jul 07 10:38:25 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-23 1235ad0bm04暂无昵称

    看看

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1062411, encodeId=61f91062411dc, content=很好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Wed Oct 20 23:18:52 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060125, encodeId=ae841060125fd, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:14:45 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012718, encodeId=8a3a1012e18bf, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUaOs097vUd3tAkBeYXo0UuMtO6vOHicpCNV0xHiaMbaxn5hqtZbIdlZ4NHjXRFMpE5u0bGLAvRUjw/132, createdBy=916a2555838, createdName=刘荣泉, createdTime=Mon Aug 30 06:08:51 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001947, encodeId=f32d100194e57, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/15/b440bceb993c400094dff18d6231a29b.jpg, createdBy=acee2402916, createdName=1235ad0bm04暂无昵称, createdTime=Fri Jul 23 10:31:45 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997045, encodeId=afab99e04530, content=想要学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=Kwok21w, createdTime=Wed Jul 07 10:38:25 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-07 Kwok21w

    想要学习

    0

拓展阅读

乳腺癌HER2检测指南(2009版)

中国肿瘤科相关专家小组(统称) · 2009-12-01

2010 乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2010版)

乳腺癌骨转移和骨相关疾病临床诊疗专家组 · 2010-01-01

2010 SBI/ACR推荐建议:乳腺癌影像学筛查

乳腺影像学会(SBI,Society of Breast Imaging) · 2010-01-20

2010 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2010-02-01

2010 ASCO-CAP指南:乳腺癌患者雌激素和雄激素受体的免疫组化检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-04-19

2010 ASCO指南:激素受体阳性乳腺癌妇女的辅助内分泌治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-07-12